Ocugen Inc

Cerrado

1.52 -5

Resumen

Variación precio

24h

Actual

Mínimo

1.54

Máximo

1.6600000000000001

Métricas clave

By Trading Economics

Ingresos

-1.5M

-19M

Ventas

1.7M

1.5M

BPA

-0.06

Margen de beneficios

-1,250.946

Empleados

116

EBITDA

-987K

-17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+479.04% upside

Dividendos

By Acuity

Próximas Ganancias

31 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-61M

565M

Apertura anterior

6.52

Cierre anterior

1.52

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 jun 2026, 23:56 UTC

Ulta Beauty shares rose in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

30 jun 2026, 23:56 UTC

Correlated Moves

After-market trading for the iShares Core U.S. Aggregate Bond ETF is roughly flat, reflecting routine performance amid slight gains in the US 2Y Treasury Bond.

30 jun 2026, 23:52 UTC

European equity indices rise as Germany's inflation falls below expectations, easing ECB tightening concerns, while Bitcoin declines amid market volatility.

30 jun 2026, 23:52 UTC

Global markets show mixed performance as European indices rise on tech optimism while U.S. stocks decline amid volatility, with the dollar strengthening against the yen and Bitcoin falling due to regulatory concerns.

30 jun 2026, 23:52 UTC

U.S. equity indices decline as tech stocks sell off, while European markets rise on positive economic data; dollar strengthens amid Fed rate hike expectations and Bitcoin drops 2.8%.

30 jun 2026, 23:52 UTC

Mixed Asia equity markets as Japan's optimism contrasts with U.S. profit-taking; Bitcoin declines amid shifting investor focus ahead of key U.S. employment data.

30 jun 2026, 23:52 UTC

Bank of Japan to release Q2 Tankan Index on June 30, with market expectations set at a stable 16.0 amid ongoing optimism in manufacturing sector.

30 jun 2026, 23:52 UTC

South Korea's Exports Expected to Surge Again Ahead of July 1 Release Amid Strong Semiconductor Demand and Positive Market Sentiment.

30 jun 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI set for July 1, with positive trends expected amid regional growth signals and inflation concerns.

30 jun 2026, 23:52 UTC

ISM Manufacturing Employment Report Set for July 1: Market Eyes Mixed Economic Signals and Job Growth Ahead of Potential Fed Rate Hikes.

30 jun 2026, 23:52 UTC

Australia's Balance of Trade data set for July 2, 2026, anticipates a AUD 2.3 billion surplus amid mixed stock market sentiment and geopolitical concerns.

30 jun 2026, 23:52 UTC

ISM Manufacturing PMI for June 2026 set to release on July 1, forecasted at 54.0 amid cautious optimism and geopolitical tensions impacting market stability.

30 jun 2026, 23:52 UTC

Brazil's BCB Focus Market Readout on July 6, 2026, may signal interest rate adjustments amid mixed investor sentiment influenced by inflation and global market pressures.

30 jun 2026, 23:52 UTC

Brazil's Industrial Production Expected to Continue Growth Trend Ahead of July 2 Release Amid Record Oil Output from Petrobras

30 jun 2026, 23:52 UTC

Canada's Manufacturing PMI Release on July 2 Expected to Reflect Economic Resilience Amid Mixed Global Signals and Geopolitical Pressures.

30 jun 2026, 23:52 UTC

ECB Forum on Central Banking Set for July 2026 Amid Cautious Market Sentiment and Potential Changes to Interest Rates.

30 jun 2026, 23:52 UTC

Japan's Current Account Data Release on July 7, 2026, Expected to Reflect Economic Trends Amidst Cautious Investor Optimism.

30 jun 2026, 23:51 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Europe ETF is lower in after-market hours, influenced by mixed returns from holdings like BCS and NOK, as well as broader market sentiment.

30 jun 2026, 23:51 UTC

ETF Constituents

Vanguard Small-Cap ETF declines after hours, impacted by significant losses in holdings like SSTK, BLDR, and TOL. Trading activity remains weak.

30 jun 2026, 23:51 UTC

ETF Constituents

VanEck Gold Miners ETF declines in after-market trading, following three consecutive lower daily closes. KGC, AEM, and NEM all recorded negative returns.

30 jun 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

30 jun 2026, 23:51 UTC

Texas Instruments Inc. shares are trading higher in after-market hours, reflecting broader positive momentum in equity indices amid optimism around economic data and AI investments.

30 jun 2026, 23:46 UTC

NetEase Inc. shares are higher in after-market trading, reflecting unusual strength following three consecutive sessions of gains amid a positive trend in European equities.

30 jun 2026, 23:46 UTC

Lululemon Athletica Inc shares are lower in after-market hours, remaining near the lower end of their one-month range and below the 20-day moving average.

30 jun 2026, 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF declines after market close, influenced by mixed global equity performance. LG Display saw a positive return, while SK Telecom had minimal impact.

30 jun 2026, 23:46 UTC

ETF Constituents

iShares China Large-Cap ETF advances in after-market trading, influenced by JD's negative contribution. FXI remains near the lower end of its one-month range.

30 jun 2026, 23:42 UTC

Australia's Ai Group Industry Index plunges to -30.0, signaling severe industrial contraction amid mixed economic signals and persistent challenges.

30 jun 2026, 23:42 UTC

MBA 30-Year Mortgage Rate Release on July 1 Expected to Show Stability Amid High Borrowing Costs and Mixed Consumer Confidence in Housing Market

30 jun 2026, 23:42 UTC

Mexican Business Confidence Remains Low at 47.5 Points Ahead of Key EMOE Report Amid Regulatory Changes and Economic Uncertainties

30 jun 2026, 23:42 UTC

Australia's Building Permits Expected to Rise 0.01% Amid Cautious Economic Sentiment and Mixed Market Indicators

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

479.04% repunte

Estimación a 12 Meses

Media 9.67 USD  479.04%

Máximo 12 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat